SBRT FOR STAGE I LUNG CANCER:
THE EVIDENCE COMPARING IT TO SURGERY
For medically inoperable patients โ and increasingly for operable ones โ SBRT delivers surgery-comparable survival with lower procedural risk and shorter treatment time.
analyticsAt a Glance
- check_circle90%+ local control at 3 years in prospective series
- check_circle3โ5 fractions, typically completed in 1โ2 weeks
- check_circleStandard of care for medically inoperable Stage I NSCLC
- check_circleComparable survival to lobectomy in propensity-matched analyses
Why SBRT Changed the Treatment of Stage I Lung Cancer
Before SBRT, patients unable to tolerate surgery faced conventional RT with local control rates under 50%. SBRT delivers ablative doses to the primary tumour in 3โ5 fractions, consistently achieving control rates that approach surgical outcomes.
โSBRT has transformed Stage I lung cancer treatment โ giving surgery-equivalent outcomes to patients once considered untreatable.โ
Medically Inoperable Patients
SBRT is the established standard for patients with Stage I NSCLC deemed inoperable due to COPD, cardiac disease, poor performance status, or patient refusal of surgery.
Operable Patients: Growing Evidence
Randomised data (STAR, ROSEL, JCOG0802) and pooled analyses suggest SBRT achieves comparable OS to lobectomy for peripheral T1 NSCLC, raising genuine equipoise in operable patients.
Key Trial and Registry Outcomes
Prospective and registry data consistently demonstrate high local control and favourable survival after lung SBRT.
Local Control at 3 Years
- RTOG 0236 (3-yr primary tumour control)97.6%
- Onishi et al. (BED โฅ100 Gy, 3-yr LC)88.4%
- JCOG0403 (3-yr LC, T1 inoperable)68.5%
Overall Survival
- SBRT 3-yr OS (inoperable, pooled)56%
- Lobectomy 3-yr OS (propensity-matched)59%
- STAR/ROSEL pooled: SBRT 3-yr OS95%
Common Lung SBRT Dose Regimens
Regimen selection depends on tumour location โ peripheral vs central (within 2 cm of bronchial tree).
| Regimen | Fractions ร Dose | BEDโโ | Best For |
|---|---|---|---|
| 3 ร 18 Gy | 54 Gy / 3 fx | 151 Gy | Peripheral T1โT2 NSCLC โ RTOG 0236 standard |
| 4 ร 12.5 Gy | 50 Gy / 4 fx | 112.5 Gy | Peripheral tumours, slightly larger volume |
| 5 ร 10 Gy | 50 Gy / 5 fx | 100 Gy | Peripheral or ultra-central โ safer toxicity profile |
| 8 ร 7.5 Gy | 60 Gy / 8 fx | 105 Gy | Central/ultra-central tumours โ reduces bronchial toxicity |
SBRT vs Lobectomy: Clinical Considerations
Understanding which approach fits the patient depends on operability, tumour location, and oncologic goals.
SBRT Advantages
- No anaesthesia or thoracotomy requiredCritical for patients with COPD, cardiac disease, or low FEV1
- Outpatient treatmentMost patients treated in 1โ2 weeks without hospital admission
- Equivalent OS in operable T1 NSCLCSTAR/ROSEL pooled analysis showed no significant survival difference
- Lower 30-day mortalityNegligible treatment-related mortality vs 1โ3% for thoracotomy
Lobectomy Advantages
- Lymph node samplingProvides pathological nodal staging โ important for occult N1/N2 disease
- Larger tumours (T2bโT3)Surgery preferred for tumours >4 cm where SBRT data is limited
- Central tumours with bronchial involvementSleeve resection may achieve better functional outcomes than central SBRT
SBRT Toxicity Profile in Lung Cancer
- <3%Grade 3+ PneumonitisWith peripheral tumours and modern planning
- 5โ10%Chest Wall ToxicityRib fracture/pain for tumours adjacent to chest wall
- <1%Treatment-Related MortalityAcross prospective series for peripheral tumours
- 10โ20%Central Tumour RiskHigher bronchial toxicity if ultra-central โ requires modified fractionation
Related SBRT Resources
Further reading on SBRT applications across cancer types.
Frequently Asked Questions
Lung SBRT Evidence
Is SBRT as effective as surgery for Stage I lung cancer?
For medically inoperable patients, SBRT achieves local control rates above 90% at 3 years โ comparable to surgical series in similar populations. For operable patients, pooled data from the STAR and ROSEL trials showed no significant difference in 3-year OS between SBRT and lobectomy, though larger randomised trials are ongoing (VALOR, POSTILV).
What is the minimum FEV1 needed to receive lung SBRT?
There is no minimum FEV1 threshold for SBRT โ unlike surgery, which typically requires FEV1 >40% predicted and DLCO >40%. SBRT has been delivered safely to patients with severe COPD (FEV1 <30%) and is a major reason it remains the only curative option for many patients with early-stage lung cancer.
Can SBRT treat central lung tumours?
Yes, but with modified fractionation. Tumours within 2 cm of the bronchial tree are classified as "central" and require more fractions at lower doses per fraction (e.g., 8 ร 7.5 Gy) to reduce bronchial toxicity. Ultra-central tumours adjacent to the mainstem bronchus or oesophagus require the most careful planning and are treated at experienced high-volume centres.
How long does lung SBRT treatment take?
Most lung SBRT regimens are completed in 3โ5 fractions over 1โ2 weeks. Each fraction takes 30โ60 minutes on the treatment table. This compares favourably with conventional RT (6โ7 weeks) and surgery (typically 5โ7 days hospitalisation plus weeks of recovery).
Is lung SBRT available in India and China?
Yes. SBRT for lung cancer is available at major academic centres in India (Tata Memorial Mumbai, Apollo Proton Chennai, HCG) and China (PUMCH Beijing, Fudan Shanghai Cancer Centre, Sun Yat-sen). CancerFax can help you identify the best centre based on your tumour characteristics and treatment history.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Is SBRT Right for Your Lung Cancer?
Upload your imaging, PFTs, and pathology reports. Our team will assess SBRT eligibility and connect you with high-volume lung SBRT centres in Asia.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.